Radiopeptide imaging and therapy in the United States

Journal of Nuclear Medicine

Volumn 52, Issue SUPPL. 2, 2011, Pages

  Graham, Michael M ^a   Menda, Yusuf ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Carcinoid; Melanoma; Neuroendocrine tumor; Peptides; Somatostatin

Indexed keywords

BOMBESIN CU 64; BOMBESIN LU 177; BOMBESIN RE 188; BOMBESIN TC 99M; DEPREOTIDE TC 99M; DOTA CU 64; DOTATATE GA 68; DOTATATE LU 177; FLUORODEOXYGLUCOSE F 18; GALLIUM EDETATE GA 68; MELANOCORTIN; OCTREOTIDE[3 TYROSINE] DOTA GA 68; OCTREOTIDE[3 TYROSINE] DOTA Y 90; OCTREOTIDE[3 TYROSINE] I 125; P2045 RE 188; P2045 TC 99M; PENTETREOTIDE IN 111; PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE CU 64; PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE TC 99M; RADIOPEPTIDE; RADIOPHARMACEUTICAL AGENT; RGD CU 64; RGD F 18; RGD I 125; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL PEPTIDE CU 64; VASOACTIVE INTESTINAL PEPTIDE I 123;

ABDOMINAL PAIN; ANGIOGENESIS; CARCINOID; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FATIGUE; FLUSHING; GASTRINOMA; HUMAN; ISOTOPE LABELING; LEUKOPENIA; LIVER METASTASIS; LUNG CANCER; LUNG TUMOR; LYMPHOCYTOPENIA; MELANOMA; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK TUMOR; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; SCINTISCANNING; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIOTHERAPY; UNITED STATES;

EID: 83755220912     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085746     Document Type: Review

References (56)

1. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994;733:138-146.
2. Tan CK, Podila PV, Taylor JE, et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology. 1995;108:1908-1916.
3. Martinez DA, O'Dorisio MS, O'Dorisio TM, et al. Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression. J Pediatr Surg. 1995;30:1580-1589.
4. Anthony LB, Martin W, Delbeke D, Sandler M. Somatostatin receptor imaging: predictive and prognostic considerations. Digestion. 1996;57(suppl 1):50-53. (Pubitemid 26183922)
5. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas - a prospective study. Ann Intern Med. 1996;125:26-34.
6. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434-440. (Pubitemid 38391905)
7. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol. 2010;17:291-297.
8. Zalom ML, Waxman AD, Yu R, Lee J, Ih G, Wolin EM. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide. Endocr Pract. 2009;15:521-527.
9. 18F- fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978-985.
10. 111In-DTPA- octreotide. Pept Res. 1996;9:144-150.
11. Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem. 1996;39:1361-1371. (Pubitemid 26112701)
12. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016-1022. (Pubitemid 126447144)
13. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224-232. (Pubitemid 29047079)
14. 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest. 2004;125:494-501.
15. 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. Nucl Med Commun. 2004;25:839-843.
16. 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med. 2009;50:397-400.
17. 99mTc-HYNIC octreotide in neuroblastoma. Ann Nucl Med. 2008;22:817-819.
18. Phelps ME, Hoffman EJ, Huang SC, Kuhl DE. ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals. J Nucl Med. 1978;19:635-647. (Pubitemid 8359615)
19. Mintun MA, Ter-Pogossian MM, Green MA, Lich LL, Schuster DP. Quantitative measurement of regional pulmonary blood flow with positron emission tomography. J Appl Physiol. 1986;60:317-326. (Pubitemid 16024052)
20. Mintun MA, Dennis DR, Welch MJ, Mathias CJ, Schuster DP. Measurements of pulmonary vascular permeability with PET and gallium-68 transferrin. J Nucl Med. 1987;28:1704-1716. (Pubitemid 17160289)
21. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147-157. (Pubitemid 34127947)
22. 68Ga-DOTATOC. J Nucl Med. 2011;52:123-131.
23. Fletcher WS, Lum SS, Nance RW, Pommier RF, O'Dorisio MS. The current status of somatostatin receptors in malignant melanoma. Yale J Biol Med. 1997;70:561-563. (Pubitemid 28515741)
24. Wei L, Miao Y, Gallazzi F, et al. Gallium-68-labeled DOTA-rhenium- cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945-953. (Pubitemid 350061168)
25. 68Ga-labeled CHX-A″-Re(Arg11)CCMSH. Nucl Med Biol. 2009;36:345-354.
26. 68Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol. 2009;36:505-513.
27. 18F-labeled metallopeptides. J Nucl Med. 2009;50:1865-1872.
28. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
29. 18F-FPRGD4). J Nucl Med. 2007;48:1536-1544.
30. Li C, Wang W, Wu Q, et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006;33:349-358.
31. Sprague JE, Kitaura H, Zou W, et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med. 2007;48:311-318. (Pubitemid 47555359)
32. 18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007;67:7833-7840.
33. 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med. 2009;50:250-258.
34. 3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging. 2009;36:1874-1884.
35. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016-1025.
36. Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer. 1997;80:2354-2359. (Pubitemid 28009486)
37. Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218-225. (Pubitemid 28147139)
38. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium-99m- bombesin analogue with low abdominal accumulation. Bioconjug Chem. 2005;16:43-50. (Pubitemid 40129676)
39. 2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 2010;30:19-30.
40. 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110-1117.
41. Hoffman TJ, Smith CJ. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol. 2009;36:579-585.
42. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-2024.
43. Praharaj S, Overbey D, Giblin MF. Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor. Future Oncol. 2010;6:1325-1337.
44. Zhang K, Aruva MR, Shanthly N, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: in vitro/in vivo evaluation. Regul Pept. 2007;144:91-100. (Pubitemid 350030981)
45. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132. (Pubitemid 34311078)
46. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008;23:292-300. (Pubitemid 351931457)
47. 90Y- edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652-1659.
48. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1018-1031.
49. Bushnell D, Menda Y, O'Dorisio T, et al. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher] [sic]) treatment. Cancer Biother Radiopharm. 2004;19:35-41. (Pubitemid 38352283)
50. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15. (Pubitemid 36692887)
51. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-2423.
52. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556-1560.
53. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156. (Pubitemid 43320450)
54. 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med. 2010;51:1524-1531.
55. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041-1047.
56. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J Thorac Oncol. 2009;4:1550-1554.